
        <!DOCTYPE html>
        <html>
        <head>
            <title>Immunovant Inc. (IMVT) - Articles</title>
            <meta name="viewport" content="width=device-width, initial-scale=1.0">
            <style>
                :root {
                    --primary-color: #000000;
                    --secondary-color: #666666;
                    --accent-color: #d5001c;
                    --text-color: #2c3e50;
                    --border-color: #e0e0e0;
                    --hover-color: #f8f9fa;
                }
                
                body { 
                    font-family: "Porsche Next", "Segoe UI", Arial, sans-serif;
                    margin: 0;
                    padding: 0;
                    color: var(--text-color);
                    background-color: #f5f6fa;
                    line-height: 1.6;
                }
                
                .header {
                    background: linear-gradient(135deg, #000 0%, #1a1a1a 100%);
                    padding: 25px 0;
                    box-shadow: 0 2px 10px rgba(0,0,0,0.2);
                    position: sticky;
                    top: 0;
                    z-index: 1000;
                    backdrop-filter: blur(10px);
                }
                
                .header::before {
                    content: '';
                    position: absolute;
                    top: 0;
                    left: 0;
                    right: 0;
                    bottom: 0;
                    background: radial-gradient(circle at 30% 50%, rgba(255,255,255,0.08) 0%, rgba(255,255,255,0) 70%);
                    pointer-events: none;
                }
                
                .header-content {
                    max-width: 1400px;
                    margin: 0 auto;
                    padding: 0 30px;
                    display: flex;
                    justify-content: space-between;
                    align-items: center;
                }
                
                .header-title {
                    font-size: 28px;
                    font-weight: 300;
                    color: #fff;
                    margin: 0;
                    letter-spacing: 1px;
                }
                
                .back-btn {
                    background: rgba(255,255,255,0.1);
                    border: 1px solid rgba(255,255,255,0.2);
                    padding: 10px 20px;
                    color: #fff;
                    text-decoration: none;
                    font-size: 14px;
                    border-radius: 4px;
                    transition: all 0.3s ease;
                    backdrop-filter: blur(5px);
                }
                
                .back-btn:hover {
                    background: rgba(255,255,255,0.2);
                    transform: translateY(-2px);
                }
                
                .container {
                    max-width: 1400px;
                    margin: 40px auto;
                    padding: 0 30px;
                }
                
                .stats-container {
                    display: grid;
                    grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
                    gap: 20px;
                    margin-bottom: 40px;
                }
                
                .stat-card {
                    background: #fff;
                    border-radius: 12px;
                    padding: 25px;
                    text-align: center;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: transform 0.3s ease;
                }
                
                .stat-card:hover {
                    transform: translateY(-5px);
                }
                
                .stat-value {
                    font-size: 32px;
                    font-weight: 300;
                    color: var(--primary-color);
                    margin-bottom: 10px;
                }
                
                .stat-label {
                    font-size: 14px;
                    color: var(--secondary-color);
                    text-transform: uppercase;
                    letter-spacing: 1px;
                }
                
                .articles-grid {
                    display: grid;
                    grid-template-columns: repeat(auto-fill, minmax(400px, 1fr));
                    gap: 30px;
                    margin-top: 40px;
                }
                
                .article-card {
                    background: #fff;
                    border-radius: 12px;
                    overflow: hidden;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: all 0.3s ease;
                }
                
                .article-card:hover {
                    transform: translateY(-5px);
                }
                
                .article-content {
                    padding: 25px;
                }
                
                .article-title {
                    font-size: 18px;
                    font-weight: 400;
                    margin: 0 0 15px;
                    line-height: 1.4;
                }
                
                .article-title a {
                    color: var(--primary-color);
                    text-decoration: none;
                    transition: color 0.2s ease;
                }
                
                .article-title a:hover {
                    color: var(--accent-color);
                }
                
                .article-meta {
                    display: flex;
                    align-items: center;
                    gap: 20px;
                    margin-bottom: 15px;
                    font-size: 14px;
                    color: var(--secondary-color);
                }
                
                .article-sentiment {
                    padding: 4px 12px;
                    border-radius: 20px;
                    font-weight: 500;
                    font-size: 14px;
                }
                
                .article-sentiment.positive {
                    background: rgba(40,167,69,0.1);
                    color: #28a745;
                }
                
                .article-sentiment.negative {
                    background: rgba(220,53,69,0.1);
                    color: #dc3545;
                }
                
                .article-sentiment.neutral {
                    background: rgba(108,117,125,0.1);
                    color: #6c757d;
                }
                
                .article-summary {
                    font-size: 14px;
                    color: var(--text-color);
                    line-height: 1.6;
                    margin-top: 15px;
                    opacity: 0.8;
                }
                
                @media (max-width: 768px) {
                    .header-content {
                        padding: 0 20px;
                    }
                    
                    .header-title {
                        font-size: 20px;
                    }
                    
                    .container {
                        padding: 0 20px;
                        margin: 20px auto;
                    }
                    
                    .articles-grid {
                        grid-template-columns: 1fr;
                        gap: 20px;
                    }
                    
                    .stat-card {
                        padding: 20px;
                    }
                    
                    .stat-value {
                        font-size: 28px;
                    }
                }
            </style>
        </head>
        <body>
            <div class="header">
                <div class="header-content">
                    <h1 class="header-title">Immunovant Inc. (IMVT)</h1>
                    <a href="sentiment_report_latest.html" class="back-btn">← Back to Dashboard</a>
                </div>
            </div>
            
            <div class="container">
                <div class="stats-container">
                    <div class="stat-card">
                        <div class="stat-value">16</div>
                        <div class="stat-label">Total Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">10</div>
                        <div class="stat-label">Positive Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">1</div>
                        <div class="stat-label">Negative Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">0.37</div>
                        <div class="stat-label">Average Sentiment</div>
                    </div>
                </div>
                
                <div class="articles-grid">
        
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=b25f8bb0b79df60405a83dbbee035857988aee3bfb549f300b1bb2b8b7358cf5" target="_blank" rel="noopener noreferrer">Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-04-08</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">We recently published a list of 10 Best Low Cost Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against other best...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=0d2cee3752538f8b5993d1f1bf07d4f8c09a0f5d431d22d4713bb2b764bffc41" target="_blank" rel="noopener noreferrer">Argenx: The Magic May Be Already Priced In</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-24</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ARGX stock here....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=3bd790079ffecfcef9f38571b448ba3797e26be75620f3273abc85a5986b57fc" target="_blank" rel="noopener noreferrer">Immunovant price target raised to $61 from $58 at Stifel</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-21</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.94
                                </span>
                            </div>
                            <div class="article-summary">Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following yesterday’s topline data from the Batoclimab Myasthtenia...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=8f81827abb6ec00be306ef52a83e31acbe2c243bf3d6f7d992305822a81d2a8e" target="_blank" rel="noopener noreferrer">Invesco Health Care Fund Q4 2024 Commentary</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-20</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment negative">
                                    -0.56
                                </span>
                            </div>
                            <div class="article-summary">Stock selection in life science tools & services, pharmaceuticals and distributors detracted from relative performance, as did an overweight in health care facilities....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=42b40f59d289c78993668954de993f2cabbc957aed4a247670ce7de7fa6d3d76" target="_blank" rel="noopener noreferrer">IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-20</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.56
                                </span>
                            </div>
                            <div class="article-summary">Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=b682128aacfaa6c5662c365d5ad5c332b9872855e1c657cf89f4b27ae8409afa" target="_blank" rel="noopener noreferrer">Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-20</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.95
                                </span>
                            </div>
                            <div class="article-summary">Immunovant (IMVT) reported best absolute improvements with IMVT-1402 in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, and while H.C. Wainwright analyst Douglas Tsao was enco...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=bdeda3736a8e41deae25ee73eb688ffbae71ec87cf28eac91489b3253d10f87e" target="_blank" rel="noopener noreferrer">Immunovant's muscle disorder treatment meets main goal in late-stage trial</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-19</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment positive">
                                    0.52
                                </span>
                            </div>
                            <div class="article-summary">Immunovant said onWednesday its drug for a type of chronic autoimmune diseaseaffecting muscles met the main goal of improving some patients'ability to perform daily activities in a late-stage......</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=5799164cef2cafe474ca23c9fc81492a811fc76fbe8305c8bc2db5d777a65777" target="_blank" rel="noopener noreferrer">Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-19</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">NEW YORK, March 19, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. on behalf of the company's shareholders. The investigation seeks to determine......</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=b08e8a218d27d22c141ef6a0b6f7cf31185135cf274dd9196420ffbc48c2a34c" target="_blank" rel="noopener noreferrer">Immunovant claims study success for immune disease drug but holds off on submission</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-19</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.36
                                </span>
                            </div>
                            <div class="article-summary">The company continues to focus on a next-generation drug while batoclimab’s testing in thyroid eye disease wraps up....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=97b2fc0ec1d464ca6cbe4bacf876a27c83bde8e420f3911210ef3d75532cbcf7" target="_blank" rel="noopener noreferrer">Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-19</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.95
                                </span>
                            </div>
                            <div class="article-summary">Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 ...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=12c5dfe12548f0b19037b18484799de9374a8a88a83abbbe1342b7ef415df74a" target="_blank" rel="noopener noreferrer">Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-19</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.91
                                </span>
                            </div>
                            <div class="article-summary">Wednesday, Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and initial results from Period 1 of its Phase 2b study in chronic inf...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=ede01e2890b795153db1e4b34765bfb8f05fc93cbd0b22831c1421d0fd7e788d" target="_blank" rel="noopener noreferrer">Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-19</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data expected in 2025. Click for my IMVT update....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=192895244908aaf92ced0ebd48e7dbb93c4399a05b41c78215d5eae1a276c126" target="_blank" rel="noopener noreferrer">Immunovant will not seek approval for MG therapy, despite hitting endpoints</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-19</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.71
                                </span>
                            </div>
                            <div class="article-summary">The company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over the trial’s batoclimab....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=d90e5fefa4b6f0b23652fda9d9bf01560e9cb5d6058c12d1a6d4bf8712ce0799" target="_blank" rel="noopener noreferrer">Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-19</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.29
                                </span>
                            </div>
                            <div class="article-summary">Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=9b86106c5db07cfe3c293549e1198a1d18cff1a2dd7286d7e4ebf1c21520fba2" target="_blank" rel="noopener noreferrer">Immunovant to Host Investor Webcast at 8: 00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-18</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment positive">
                                    0.36
                                </span>
                            </div>
                            <div class="article-summary">NEW YORK, March 18, 2025 -- Immunovant, Inc. , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an......</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=66e12ff9f5808f504351eae93ab5fe7c3360184816bb196351a0750d19055063" target="_blank" rel="noopener noreferrer">Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-18</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...</div>
                        </div>
                    </div>
            
                </div>
            </div>
        </body>
        </html>
        